French drugmakers join forces on drug with potential to treat autism in children

23 March 2017

Servier, France’s largest independent pharma company, has entered into a partnership to accelerate the development of a medicine that could become the first treatment for the core symptoms of autism.

It has signed an exclusive agreement with Marseille-based Neurochlore to develop and market bumetanide in pediatric autism in Europe.

The terms of the agreement state that Servier will develop and market the product in Europe and Neurochlore will retain these rights for the USA. Rights in relation to other countries are still under negotiation. The development plan includes three Phase III trials with an oral liquid form designed for children. Filing for marketing authorization is envisaged for the end of 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK